The metastatic bone niche presents a harsh milieu marked by hypoxia and scarce nutrient availability, challenging the survival of disseminated tumor cells. To overcome these constraints, metastatic breast cancer cells have evolved remarkably versatile strategies. Kang, Han, and their colleagues employed meticulous cellular and molecular analyses to dissect how these cancer cells manipulate specialized bone marrow components to extract metabolic support vital for their growth. Their findings, detailed in the prestigious journal Cell, reveal a dual mechanism by which breast cancer cells subvert normal hematopoietic processes—directly impairing red blood cell production and simultaneously enhancing their own survival capacity within the oxygen-deprived marrow.

Crucial to this malignant adaptation is the exploitation of erythroblast island (EBI) macrophages, a specialized subset of immune cells embedded in the bone marrow niche. Under physiological conditions, EBI-macrophages serve a nurturing role, recycling iron and supplying it to erythroblasts—the precursors of red blood cells—facilitating hemoglobin synthesis crucial for oxygen transport. However, the research unveils that metastatic breast cancer cells ‘hijack’ these macrophages to reroute iron resources exclusively to themselves. This metabolic commandeering deprives erythroblasts of iron, undermining effective erythropoiesis and precipitating anemia. Han emphasizes this point, noting that experimental depletion of EBI-macrophages in murine models significantly curtailed breast cancer bone metastases, underscoring their centrality in tumor sustenance.

Beyond mere iron scavenging, metastatic tumor cells also demonstrate phenotypic plasticity by mimicking erythroblast-like characteristics. One astonishing discovery in this study is the aberrant expression of β-globin, a hemoglobin subunit typically restricted to red blood cells, by metastatic cancer cells in the hypoxic marrow environment. This ectopic β-globin expression is hypothesized to confer a survival advantage by enhancing intracellular oxygen handling and mitigating oxidative stress, an adaptation that correlates strongly with increased bone metastasis risk in human clinical samples. The researchers propose that this form of ‘molecular mimicry’ is a critical facet enabling cancer cells to thrive where oxygen is limited.

The synergy of these two strategies—metabolic hijacking of EBI-macrophages to monopolize iron and the adoption of erythroid properties to endure hypoxia—creates a pernicious feedback loop. Iron acquisition fuels tumor proliferation while simultaneously starving erythroblasts of a vital hematopoietic substrate, exacerbating anemia in patients. This disruption of normal bone marrow function elucidates a heretofore obscure axis of tumor-immune-metabolic cross-talk integral to metastatic progression. Kang elaborates that this discovery not only deepens fundamental understanding of bone metastasis biology but also paves the way for therapeutic interventions aimed at decoupling tumor growth from marrow dysfunction.

Intriguingly, the phenomenon of EBI-macrophage hijacking appears to transcend breast cancer, with analogous observations in bone metastases arising from lung and kidney carcinomas. This suggests a conserved metastatic strategy among diverse solid tumors colonizing the bone microenvironment. Given the prevalence of cancer-induced anemia and the clinical challenges it poses, targeting the metabolic interactions between tumor cells and the bone marrow niche holds considerable promise. Disrupting these pathological iron fluxes or impeding β-globin expression could restore erythropoiesis while stifling tumor expansion.

From a translational perspective, these insights highlight novel biomarkers and molecular targets. Elevated β-globin in tumor cells could serve as a prognostic indicator for bone metastatic potential. Furthermore, therapies designed to modulate EBI-macrophage function may protect hematopoietic integrity without compromising anti-cancer efficacy. Such approaches align with the emerging paradigm of metabolic vulnerability exploitation, supplementing existing modalities focusing on genetic and immunologic tumor characteristics.

The study by Kang and Han exemplifies the integrative research paradigm bridging cellular biology, immunology, and cancer metabolism. By deploying a combination of in vivo models, patient sample analyses, and cutting-edge molecular profiling, the team elucidated the sophisticated ecological niche created by metastatic cells within bone marrow. Their work underscores the remarkable plasticity of metastatic cells, adept at remodeling their immediate environment to their advantage through metabolic and phenotypic reprogramming.

As therapies evolve to meet the challenges of metastatic disease, unraveling such complex tumor-host interactions becomes imperative. Anemia, often overshadowed by other clinical concerns, is now recognized as a direct consequence of tumor biology rather than merely a byproduct of bone marrow damage. Addressing these mechanisms could profoundly impact patient quality of life and survival outcomes, a dual victory in the battle against metastatic breast cancer.

This research was supported by a consortium of philanthropic and scientific foundations including the Ludwig Institute for Cancer Research, American Cancer Society, and Susan G. Komen Foundation. Yibin Kang, beyond his membership at the Ludwig Institute, holds the prestigious Warner-Lambert/Parke-Davis Professorship at Princeton University and serves as Associate Director at Rutgers Cancer Institute of New Jersey, underscoring the institutional commitment to advancing metastatic cancer research.

In conclusion, the unveiling of tumor-driven metabolic manipulation within the bone marrow niche sheds critical light on how breast cancer metastasis undermines normal physiology, particularly red blood cell production, through iron theft and erythroid mimicry. This discovery not only expands the conceptual framework of metastatic adaptation but also opens new therapeutic vistas aimed at disrupting the lethal synergy between tumor progression and cancer-associated anemia.

Subject of Research: Metabolic interactions between metastatic breast cancer cells and the bone marrow microenvironment leading to anemia and tumor proliferation.

Article Title: Breast Cancer Metastases Exploit Bone Marrow Iron Recycling and Erythroid Mimicry to Promote Anemia and Tumor Survival.

News Publication Date: September 3, 2025.

Web References:

• Ludwig Institute for Cancer Research: https://www.ludwigcancerresearch.org/scientist/yibin-kang/
• Original article in Cell: https://www.cell.com/cell/abstract/S0092-8674(25)00927-4

References: Available upon request from Ludwig Cancer Research publications.

Image Credits: Ludwig Cancer Research (Photo of Yibin Kang).

Keywords: Breast cancer, bone metastasis, anemia, erythroblast island macrophages, iron metabolism, β-globin expression, tumor microenvironment, metabolic adaptation, erythropoiesis disruption, metastatic progression, cancer metabolism, hematopoiesis, tumor-immune interaction.

Histone lactylation, a relatively new post-translational modification, has emerged as a significant player in gene regulation and chromatin dynamics. This modification could profoundly impact how cancer cells orchestrate the immune response. The findings of Zhou et al. suggest that histone lactylation can suppress the ubiquitination of NCAPG, a key protein involved in cell cycle regulation. By mitigating NCAPG ubiquitination, CAFs essentially create a conducive environment for tumors to thrive while dodging the vigilance of the immune system.

Gastric cancer represents a formidable challenge, not only due to its late-stage diagnosis but also because of its complex tumor microenvironment. The contribution of CAFs in this environment cannot be overstated. These fibroblasts, often activated during inflammation and tumorigenesis, can secrete a variety of cytokines, chemokines, and growth factors that have a profound impact on tumor progression. CAFs orchestrate the immune landscape in such a manner that it fosters an immunosuppressive milieu, ultimately leading to poorer patient outcomes.

The research emphasizes the interplay between CAFs and tumor cells through a series of signaling pathways that involve not only histone modifications but also metabolic changes within the tumor microenvironment. It is becoming increasingly clear that these fibroblasts are not just passive support cells; rather, they actively participate in tumor bioenergetics and immune modulation. By studying the molecular circuitry involving histone lactylation and NCAPG, the authors provide a fresh perspective on potential therapeutic interventions aimed at reversing immune evasion.

Understanding the nuances of CAF-mediated immune evasion can help identify novel biomarkers for early detection of gastric cancer. Furthermore, the potential exploitation of histone modification pathways represents a promising avenue for therapeutic development. The realization that tumors can hijack normal cellular processes for their survival highlights the intricate balance between host defenses and cancer strategies. For instance, the histone lactylation process offers a target for pharmacological intervention; inhibiting this modification could restore a more robust immune response against tumor cells.

Another significant finding from the study is the potential of targeting the metabolic pathways linked to CAF activity. Cancer cells are known for their altered metabolism, often referred to as the Warburg effect, where they preferentially utilize glycolysis even in the presence of sufficient oxygen. CAFs also exhibit adaptive metabolic reprogramming that supports cancer growth. This metabolic interplay between CAFs and tumor cells represents an exciting frontier for therapeutic strategies aimed at disrupting this symbiotic relationship.

In terms of clinical implications, the research opens up several possibilities for combination therapies, which may involve oncogene inhibitors paired with agents that target CAF-driven pathways. By simultaneously attacking the cancer cells and the supportive stromal elements, it may be possible to enhance the efficacy of existing treatments, providing new hope for patients facing this aggressive disease.

The role of epigenetic modifications, particularly histone lactylation, extends beyond gastric cancer, entering the wider realm of oncology research. Investigators are now tasked with understanding how these modifications operate in various cancers and how they might be manipulated to favor anti-tumor immunity. The body of literature around histone modifications in cancer is rapidly expanding, promising to reveal deeper insights into cancer biology and potential therapeutic avenues.

Future research must aim to elucidate the comprehensive regulatory networks in which histone lactylation operates, including interactions with other epigenetic alterations such as methylation and acetylation. Establishing these connections will provide a clearer roadmap towards understanding how tumors confer resistance to therapies that initially appear effective. As scientists delve deeper into these mechanisms, we can expect a more sophisticated arsenal of treatment options tailored to exploit the vulnerabilities in these cancer-promoting pathways.

In conclusion, the study by Zhou et al. presents groundbreaking insights into the molecular dynamics of gastric cancer, emphasizing CAFs as key players in immune evasion through histone lactylation and NCAPG suppression. By unveiling these mechanisms, the research not only highlights the complexity of tumor biology but also paves the way for targeted therapies aimed at dismantling the immunosuppressive tactics employed by cancers. As the field of cancer immunology continues to evolve, the findings could serve as a catalyst for innovative approaches to treat gastric and potentially other types of cancers, ultimately striving for improved outcomes for patients.

Subject of Research: Role of cancer-associated fibroblasts in immune evasion in gastric cancer.

Article Title: CAFs promote immune evasion in gastric cancer through histone lactylation-mediated suppression of NCAPG ubiquitination.

Article References:

Zhou, S., Xiao, L., Hu, L. et al. CAFs promote immune evasion in gastric cancer through histone lactylation-mediated suppression of NCAPG ubiquitination. J Transl Med 23, 989 (2025). https://doi.org/10.1186/s12967-025-07013-0

Image Credits: AI Generated

DOI: 10.1186/s12967-025-07013-0

Keywords: Gastric cancer, cancer-associated fibroblasts, immune evasion, histone lactylation, NCAPG ubiquitination.